Novartis Thinks It Can Do Better With GSK’s Oncologics Than GSK Did
This article was originally published in The Pink Sheet
Novartis stresses the blockbuster potential, in its hands, of three products – Votrient, Tafinlar and Mekinist – that it is acquiring from GSK as part of its narrowed focus on innovative pharmaceuticals, eye care and generics, and the divestment of vaccines, OTCs and animal health.
You may also be interested in...
Pfizer’s Latest Palbociclib Data Could Mean Slimmer Lead Over CDK4/6 Rivals
Final Phase II data for palbociclib in breast cancer at AACR meeting raise questions about prospects for accelerated approval prior to Phase III results. Meanwhile, Lilly’s bemaciclib emerges as potent monotherapy with seemingly lower risk for neutropenia, but more data are needed to flesh out the drug’s profile.
Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.
Novartis Ups The Ante In Immunotherapy With CoStim Buy
The European pharma is increasing its stake in cancer immunotherapy with the acquisition of a start-up biotech that brings over late-stage assets against several targets.